Lineage Cell Therapeutics, Inc. Unrealized Gain (Loss) on Investments
Lineage Cell Therapeutics, Inc. (LCTX) reported Unrealized Gain (Loss) on Investments of $8.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2021-03-11
- Lineage Cell Therapeutics, Inc. unrealized gain (loss) on investments for the quarter ending 2019-12-31 was $0.00.
- Lineage Cell Therapeutics, Inc. unrealized gain (loss) on investments for the quarter ending 2019-09-30 was -$8.29M.
- Lineage Cell Therapeutics, Inc. unrealized gain (loss) on investments for fiscal 2019 was $8.00M.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$8.29M derived: sum of 2 quarters · filed 2021-03-11 | $8.00M 10-K · filed 2021-03-11 | |
| 2019-09-30 | -$8.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $8.00M 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | $16.29M 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |